Menu

News and insights

Updates from Syncona and our portfolio companies

Filter by:

Type

Topic

Company

Reset
Quell

26.10.2020

Quell Therapeutics Enters a Collaborative Research Agreement with the University of Sheffield

Quell Therapeutics, a biotechnology company developing engineered T regulatory (Treg) cell therapies, today announced that the company has entered into a collaborative research agreement with the Sheffield Institute for Translational Neuroscience (SITraN), an international centre of excellence within the University of Sheffield recognised for its ground-breaking work in the fight against neurodegenerative disorders. Under the terms of the agreement, Quell Therapeutics will collaborate in a joint research programme with SITraN to accelerate the validation of Quell’s engineered Treg cell therapy platform for use in the treatment of neuroinflammatory diseases.
Quell

11.06.2020

Quell Therapeutics strengthens its Board with the appointments of Dr Dhaval Patel and Sir Robert Lechler and hires Dr Natalie Belmonte as SVP Research & Translation

Quell Therapeutics, a biotechnology company developing engineered T regulatory (Treg) cell therapies, today announced the appointments of seasoned industry expert, Dr Dhaval Patel, Executive Vice President and Chief Scientific Officer UCB S.A. (Brussels, Belgium), and Senior Clinical Academic, Professor Sir Robert Lechler, Senior Vice President/Provost (Health) and Executive Director of King's Health Partners Academic Health Sciences Centre, to its Board of Directors.
Quell

19.05.2020

Quell Corporate Presentation

Download (1.06Mb)
Quell

08.04.2020

Quell Therapeutics Enters a Collaborative Research Agreement with the Hannover Medical School

London and Hannover – April 7 2020 – Quell Therapeutics, a biotechnology company developing engineered T regulatory (Treg) cell therapies, today announced that the company has entered into a collaborative research agreement with Hannover Medical School (MHH). Under the terms of the agreement, Quell Therapeutics will collaborate in joint research with MHH to accelerate the discovery and validation of multiple Chimeric Antigen Receptor (CAR)-Treg cell therapies.
Quell

15.10.2019

Quell Therapeutics and an emerging area of cell therapy

Syncona speaks to one of Quell Therapeutics’ academic founders, Alberto Sanchez-Fueyo, about his career, the potential of T-regulatory cells and his vision for the business.
Quell

15.10.2019

Founding Quell Therapeutics

Syncona’s Chief Executive, Martin Murphy and Syncona Partner, Elisa Petris talk through the process for founding our innovative cell therapy company, Quell Therapeutics.
Quell

23.09.2019

Quell Therapeutics named a “Fierce 15“ Company by FierceBiotech

Quell Therapeutics, a biotechnology company focused on developing engineered T regulatory (Treg) cell therapies, announces that it has been named by FierceBiotech as one of 2019’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.
Quell

13.06.2019

Quell Therapeutics, founded by Syncona Ltd, appoints Chief Executive

Building a team of leading experts in the field of Regulatory T cell-based therapy and biology London, 13 June 2019 – Quell Therapeutics, a biotechnology company focused on developing engineered T regulatory (Treg) cell therapies, announces the appointment of Iain McGill, as Chief Executive. Iain is a leading pharmaceutical executive with extensive relevant experience having spent the majority of his 25 years in the industry in the area of solid organ and cell transplantation.